Form 4: Mary Agnes Wilderotter Acquires Stock Options in Sana Biotechnology

Director Mary Agnes Wilderotter acquired stock options for 54,278 shares of Sana Biotechnology, Inc. on June 6, 2024.

Summary

• Mary Agnes Wilderotter, a director of Sana Biotechnology, Inc., reported the acquisition of stock options.
• The transaction occurred on June 6, 2024.
• Wilderotter acquired options for 54,278 shares of common stock at an exercise price of $7.36.
• The options vest on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
• Following the transaction, Wilderotter directly owns options for 54,278 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The acquisition of stock options by a director is generally viewed neutrally to slightly positive, as it aligns the director's interests with those of the shareholders.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It is common for directors and officers of publicly traded companies to receive stock options as part of their compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates